Leanbio Invests €20 Million in Its GMP Biological Plant in Barcelona

Leanbio, the company that provides comprehensive development and manufacturing services for biological products for the pharmaceutical and biopharmaceutical sectors added €20 million of investment to its plant, currently in construction, in Sant Quirze del Vallès (Barcelona), according to the company’s statement.

In its more than 3,500 square meters, the plant will house three production lines that will have the capacity to manufacture both recombinant proteins and antibodies in different expression systems, as well as plasmid DNA and messenger RNA for advanced therapies within the biopharmaceutical sector. In addition, it will include development laboratories, scaling areas, production and quality control pilot plants.

The infrastructure, which will be fully operational from 2025, will have three lines of action dedicated to working with mammalian cells, microbial cultures and molecules for gene therapy. In this way, Leanbio will have a boost for its growth as a developer of technology, processes and biological products for third parties.

In this direction, the company is based on the application of innovative technological platforms in order to develop and manufacture biological products from the initial states to the most advanced stages, covering all phases of its cycle.

Read more about Leanbio and find the latest financial news of the day with our companion app Born2Invest, available for free for both Android and iOS devices.

Leanbio hopes to have the infrastructure fully operational from 2025

Leanbio expands its production capacity in response to a growing demand for global projects to serve both multinationals and start ups< /span>. In this sense, the company already has agreements with global companies in the manufacture of innovative biologicals and biosimilars

According to the European Biotech index of Cphi, the largest pharmaceutical hub in the world, Barcelona is already the second best European location for investment in biotechnology, only behind London and very ahead of the traditionally thriving hubs of Berlin, Paris and the Swiss capitals.

In the same vein, according to a survey carried out by the same entity to executives of pharmaceutical companies around the world, the forecasts are that Barcelona will not only consolidate itself as the capital of southern Europe within the sector, but continues its rise as a biotechnology center of global importance.

This installation is the first of its kind in the technology hub of Barcelona and aims to cover a historical gap in the region’s sector, collaborating in the consolidation of the cluster as a pole for attracting biotechnological talent, research and investment.

__

(Featured image by Logan Armstrong via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.